A review on epidemiology, diagnosis and treatment of hepatitis D virus infection

Eskandar Hajiani; Seyed Mohammad Alavi

Jundishapur Journal of Microbiology

Ahvaz Jundishapur University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Editors & Boards Journal Information Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

A review on epidemiology, diagnosis and treatment of hepatitis D virus infection

Author(s):

Eskandar Hajiani^1,*,

Seyed Mohammad Alavi²

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Emam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, ehajiani@gmail.com, Iran

2Jundishapur Infectious and Tropical Diseases Research Centre, Ahvaz Jundishapur University of Medical Sciences, Iran

Jundishapur Journal of Microbiology:Vol. 4, issue Suppl; 1-8

Article type:Review Article

How to Cite:Eskandar HajianiSeyed Mohammad AlaviA review on epidemiology, diagnosis and treatment of hepatitis D virus infection.Jundishapur J Microbiol.4(Suppl):1-8.

Abstract

Hepatitis D Virus (HDV) infection is a widespread disease that has affected a large number of population with hepatitis B Virus (HBV) infection in Iran. Disease is considered to be a major public health problem in Iran. Delta hepatitis is the least common form of chronic viral hepatitis and is the form most likely to lead to cirrhosis. Delta hepatitis is serologically complex, so effective therapy is difficult. The diagnosis is made on the basis of the presence of antibodies against HDV (anti-HDV) and hepatitis B surface antigen (HBsAg) in the serum of a patient with chronic liver disease. It is confirmed by the presence of the HDV antigen in liver or HDV RNA in the serum (by reverse-transcriptionpolymerase-chain-reaction assay). It is important to determine whether delta hepatitis is present because the responses to therapy of patients with this disease are less satisfactory than those with hepatitis B, and the recommended regimen of interferon alfa is different. The optimal treatment of HDV is uncertain. Thus, patients should ideally be treated as part of a clinical trial. The only treatment approved for chronic HDV is interferon alfa. Treatment should be administered for one year; whether longer duration of treatment will improve response rates remains to be established. Available data have not demonstrated an advantage from the addition of a nucleos/tide analogue.

Keywords

Hepatitis D Virus infection (HDV)

Hepatitis B Virus infection (HBV)

Chronic hepatitis

Khuzestan

Iran

Full Text

Full text is available in PDF

comments